Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

COM902

Monoclonal antibody · developed by Compugen

Phase 1 Most advanced trial (none active)
CGEN Developer
1 Registered trials

What is COM902?

COM902 is an agent given intravenously every 3 weeks as monotherapy in dose-escalation and cohort-expansion studies in subjects with advanced cancers, including multiple myeloma and other solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Therapy area
Oncology
Developer
Compugen Ltd (CGEN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04354246 Phase 1 Advanced Cancer Completed CGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced CancerColon CancerHNSCCLung CancerMicrosatellite Stable Colorectal CarcinomaMSS-CRCMultiple MyelomaOvarian CancerPlasma Cell Neoplasm

More from Compugen

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CGEN page.

Follow CGEN, the company behind COM902

See CGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CGEN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.